• If you are wondering whether Natera's current share price reflects its real value, you are not alone. This article will help you frame that question clearly.
• Natera's share price last closed at US$216.10, with a 7 day return of 0.1% decline, a 30 day return of 10.1% decline, a year to date return of 5.6% decline, and a 1 year return of 38.0%, alongside a very large 3 year return and a 111.6% return over 5 years.
• Recent headlines around Natera have kept the stock on many investors' watchlists. They provide context for both shorter term pullbacks and the stronger multi year return profile. These stories are an important backdrop when you weigh up whether the current price still makes sense for your own risk and return preferences.
• Natera currently has a valuation score of 1 out of 6, which means it screens as undervalued on only one of six checks. Next we will look at how different valuation approaches view the stock and then finish with a way of thinking about value that goes beyond any single model.

Natera scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Natera Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today using a required rate of return, giving an estimate of what the business might be worth in total right now.

For Natera, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The company’s latest twelve month free cash flow is about $108.7 million. Analyst estimates and Simply Wall St extrapolations project free cash flow reaching $971 million in 2030, with intermediate years such as 2026 and 2027 modeled at $158 million and $281.5 million respectively, before further estimated increases out to 2035.

Discounting these projected cash flows back to today results in an estimated intrinsic value of about $214.88 per share. Compared with the recent share price of $216.10, the model suggests Natera is roughly 0.6% overvalued, effectively pointing to a price that is very close to the DCF estimate.

Result: ABOUT RIGHT

Natera is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Natera Price vs Sales

For companies that are still building towards consistent profitability, the P/S ratio is often a useful way to compare what the market is paying for each dollar of revenue. It sidesteps short term earnings volatility and focuses on the current size of the business rather than its accounting profit.

Investors usually accept a higher or lower P/S ratio depending on what they expect for future growth and how much risk they see in the business. Faster expected growth or lower perceived risk can justify a higher multiple, while slower expected growth or higher risk tends to point to a lower, more conservative range.

Natera currently trades on a P/S ratio of 14.12x. That sits above the Biotechs industry average of 12.58x, while the peer group used here averages 19.66x. Simply Wall St also calculates a proprietary “Fair Ratio” of 8.37x for Natera. This Fair Ratio blends factors such as earnings growth estimates, profit margins, industry, market cap and company specific risks, so it can be more tailored than a simple comparison to peers or a broad industry figure.

Compared with this Fair Ratio of 8.37x, Natera’s current P/S of 14.12x screens as higher.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Natera Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Natera to the numbers by linking your view on its future revenue, earnings and margins to a forecast and a Fair Value, then comparing that to the current price. There are multiple Narratives on the Community page, ranging from very optimistic views that see Fair Value around US$300 to far more cautious ones closer to about US$115. These all update as fresh news or earnings arrive, so you can quickly see how people with different assumptions might decide whether the latest price looks high, low or roughly in line with their expectations.

For Natera however we'll make it really easy for you with previews of two leading Natera Narratives:

Each one ties a clear story to the same share price, so you can decide which set of assumptions feels closer to your own view on the stock.

Fair value in this bull narrative: about US$257.20 per share

Price vs this fair value: roughly 15.9% undervalued based on the last close of US$216.10

Revenue growth assumption used: 18.18% a year

• Focuses on Natera as an established diagnostics company with a strong position in molecular residual disease and organ health testing, supported by growing adoption of advanced molecular diagnostics.
• Builds in higher long term revenue growth and improving profit margins, alongside clinical trial progress, expanded reimbursement and use of AI and automation to improve efficiency.
• Highlights that the analyst consensus price target sits above the last close, but also flags a wide range of analyst views and encourages you to test their assumptions against your own expectations.

Fair value in this bear narrative: about US$194.59 per share

Price vs this fair value: roughly 11.1% overvalued based on the last close of US$216.10

Revenue growth assumption used: 16.55% a year

• Treats Natera as a diagnostics company facing tighter regulation, healthcare cost pressure and higher compliance demands that could weigh on revenue growth, pricing power and margins.
• Assumes that competition, high fixed R&D and operating costs and premium expectations could limit the benefit of revenue growth for long term earnings.
• Anchors on a more cautious analyst fair value that is below the last close and frames the current share price as embedding high expectations that may be hard to meet.

If you want to see how other investors are connecting these stories to their own fair value ranges, Curious how numbers become stories that shape markets? Explore Community Narratives can be a useful next step.

Do you think there's more to the story for Natera? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.